Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Renal Impairment Study (MK-0616-020)
NCT05934292
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
33
Enrollment
INDUSTRY
Sponsor class
Conditions
Hypercholesterolaemia
Interventions
DRUG:
Enlicitide Decanoate
Sponsor
Merck Sharp & Dohme LLC